Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Shazia Nakhoda, MD; Shruti Gupta, MD, MPH; and Anitha Varghese, MSN, APRN, AGPCNP-C, discuss prevention and treatment of acute kidney injury in patients receiving high-dose methotrexate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine supportive care requirements for patients with cancer receiving treatment with high-dose methotrexate (HDMTX)
• Integrate online clinical support tools, such as mtxpk.org, to aid identification of delayed methotrexate clearance
• Apply guideline-based recommendations to manage oncologic emergencies in adult and pediatric patients with delayed methotrexate clearance following HDMTX administration

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from SERB Pharmaceuticals.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Instructions on How to Receive Credit

1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 4528.
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.

You may immediately download your certificate.

Shazia Nakhoda, MD

Assistant Professor, Malignant Hematology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, BeiGene; Grant/Research Funding: BeiGene, BTG/SERB, Genentech

Shruti Gupta, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Director of Onconephrology
Brigham and Women’s Hospital and Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion, Arsenal Bio, BTG, MediBeacon, Mersana Therapeutics, Orion Pharma; Grant/Research Funding: AstraZeneca,BTG, Janssen; Executive Role (unpaid):President Emeritus and Co-Founder of American Society of Onconephrology

Anitha Varghese, MSN, APRN, AGNP-C

Advanced Practice Provider
MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: SERB Pharmaceuticals

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

Release Date

January 30, 2026

Expiration Date

January 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.